Centessa Pharmaceuticals plc

Alkermes’s initial release of Phase II trial results for alixorexton in narcolepsy type 1 (NT1) indicates that the company’s drug could prove highly competitive in the growing race among developers of

Takeda is already in launch preparations for oveporexton as the drug produced positive results in two Phase III trials in narcolepsy type 1 (NT1), making approval likely while also clearing the way fo

“How does it feel that you have a billion-dollar neuroscience commercial business, and no one cares?” That’s the question an investor asked Alkermes’ chief operating officer Blair Jackson at the recen

Biopharmaceutical companies celebrated recent positive data readouts with a slew of significant follow-on public offerings (FOPOs), including Nuvalent, Inc. , which grossed $500m on 16 September from